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Abstract
Rationale: The majority of antibiotic use in the dairy industry is for intramammary infections (IMI), with a
large portion of this aimed at treating and preventing IMI during the dry period (Lam et al., 2102). During
dry off, formation of the teat-canal keratin plug plays an important role in susceptibility to IMI (Huxley et al.,
2002), but there is wide variation between cows on time to complete closure of the teat-canal, or indeed if
closure occurs at all (Dingwell et al., 2003). In heifers, pre-partum IMI is an important risk factor for the
development of clinical mastitis in early lactation, and the impact of this disease on future udder health and
productivity is far greater than in multiparous animals (Piepers et al., 2009). Moreover, the incidence of
clinical mastitis at freshening in heifers is roughly double that of multiparous cows (Ali Naqvi et al., 2018).
Teat sealants provide a non-antibiotic strategy to prevent IMI in the pre-calving period, which is of increasing
importance due to concern for antimicrobial use and its relationship with the development of antimicrobial
resistance (WHO, 2015). Understanding the efficacy of these products is essential to optimizing their use in
order to decrease reliance on antibiotics for both treatment and prevention. Systematic reviews of randomized
controlled trials in these areas will yield the highest level of evidence for efficacy of treatment under field
conditions (Sargeant and O’Connor, 2014). Establishing the efficacy of teat sealants at dry-off, and pre-
partum in heifers, to reduce the incidence of both clinical mastitis and/or IMI, will serve to improve decision
makers’ ability to engage in effective stewardship of antibiotics thorough the strategic use of non-antibiotic
alternatives.
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Author	contributions:	
All	authors	contributed	to	the	development	of	the	review	question	and	the	methodology	
described	in	this	proposal.		HW	and	JG	developed	the	search	strategy.	JMS	drafted	the	protocol,	
with	input	and	final	approval	of	all	co-authors.	
	
Registration:		
This	protocol	is	archived	in	the	University	of	Guelph’s	institutional	repository	(The	Atrium;	
https://atrium.lib.uoguelph.ca/xmlui/handle/10214/10046)	and	published	online	with	
Systematic	Reviews	for	Animals	and	Food	(SYREAF)	available	at:		http://www.syreaf.org/.	The	
systematic	review	will	be	reported	using	the	Preferred	Reporting	Items	for	Systematic	Reviews	
and	Meta-Analyses	(PRISMA)	statement	guidelines	(Liberati	et	al.,	2009).		This	protocol	is	
reporting	using	the	items	(headings)	recommended	in	the	PRISMA-P	guidelines	(Moher	et	al.,	
2015).	
	
Support.		Funding	support	for	this	systematic	review	/	meta-analysis	/	network	meta-analysis,	
including	the	development	of	the	protocol,	was	provided	by	The	Pew	Charitable	Trusts.	
	
Introduction.	
	
Rationale:	The	majority	of	antibiotic	use	in	the	dairy	industry	is	for	intramammary	infections	
(IMI),	with	a	large	portion	of	this	aimed	at	treating	and	preventing	IMI	during	the	dry	period	
(Lam	et	al.,	2102).		During	dry	off,	formation	of	the	teat-canal	keratin	plug	plays	an	important	
role	in	susceptibility	to	IMI	(Huxley	et	al.,	2002),	but	there	is	wide	variation	between	cows	on	
time	to	complete	closure	of	the	teat-canal,	or	indeed	if	closure	occurs	at	all	(Dingwell	et	al.,	
2003).		In	heifers,	pre-partum	IMI	is	an	important	risk	factor	for	the	development	of	clinical	
mastitis	in	early	lactation,	and	the	impact	of	this	disease	on	future	udder	health	and	
productivity	is	far	greater	than	in	multiparous	animals	(Piepers	et	al.,	2009).		Moreover,	the	
incidence	of	clinical	mastitis	at	freshening	in	heifers	is	roughly	double	that	of	multiparous	cows	
(Ali	Naqvi	et	al.,	2018).			
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Teat	sealants	provide	a	non-antibiotic	strategy	to	prevent	IMI	in	the	pre-calving	period,	which	is	
of	increasing	importance	due	to	concern	for	antimicrobial	use	and	its	relationship	with	the	
development	of	antimicrobial	resistance	(WHO,	2015).	Understanding	the	efficacy	of	these	
products	is	essential	to	optimizing	their	use	in	order	to	decrease	reliance	on	antibiotics	for	both	
treatment	and	prevention.	Systematic	reviews	of	randomized	controlled	trials	in	these	areas	
will	yield	the	highest	level	of	evidence	for	efficacy	of	treatment	under	field	conditions	(Sargeant	
and	O’Connor,	2014).		Establishing	the	efficacy	of	teat	sealants	at	dry-off,	and	pre-partum	in	
heifers,	to	reduce	the	incidence	of	both	clinical	mastitis	and/or	IMI,	will	serve	to	improve	
decision	makers’	ability	to	engage	in	effective	stewardship	of	antibiotics	thorough	the	strategic	
use	of	non-antibiotic	alternatives.					
	
Objectives:		The	objective	of	this	protocol	is	to	describe	the	methods	for	a	systematic	review	–	
network	meta-analyses	to	address	the	efficacy	of	internal	or	external	teat	sealants	at	dry	off	to	
prevent	new	IMI	and	clinical	mastitis	early	in	the	subsequent	lactation.	 
			The	specific	PICO	elements,	which	will	define	the	eligibility	criteria,	are	as	follows:	
i. Population:	Pre-partum	heifers	and	dairy	cows	after	their	first	(or	greater)	lactation	
without	existing	IMI.		
ii. Intervention:	Internal	or	external	teat	sealant	given	to	heifers	pre-partum	or	dairy	cows	at	
the	time	of	dry	off.	
iii. Comparator:		No	teat	sealant,	placebo,	or	an	alternative	treatment	(such	as	an	antibiotic	
dry-cow	preparation).		
iv. Outcomes:		Critical	outcomes	will	include	i)	incidence	of	IMI	during	the	pre-calving	period	
immediately	following	the	intervention,	ii)	incidence	of	IMI	during	the	first	30	days	of	the	
subsequent	lactation	and	iii)	incidence	of	clinical	mastitis	during	the	first	30	days	of	the	
subsequent	lactation.		Secondary	outcomes	will	include	total	antibiotic	use	during	the	
first	30	days	of	the	subsequent	lactation,	milk	production	during	the	subsequent	
lactation,	somatic	cell	count	during	the	first	test	of	the	subsequent	lactation	or	the	
average	of	the	first	3	tests	of	the	subsequent	lactation,	and	the	risk	of	culling	due	to	
mastitis	during	the	subsequent	lactation.	
	
Methods	
	
Eligibility	criteria:		In	addition	to	eligibility	criteria	as	described	in	the	PICO	elements	described	
above,	eligibility	criteria	will	include	publication	in	English.		Both	published	and	non-published	
(grey	literature)	studies	are	eligible,	provided	they	report	the	results	of	a	primary	research	
study	with	a	concurrent	comparison	group	using	an	eligible	study	design.			
	
Study	designs	eligible:		Controlled	trials	with	natural	disease	exposure	will	be	eligible.		During	
full-text	eligibility	screening,	we	will	identify	studies	that	appear	to	address	the	review	
questions	but	using	an	observational	design	or	an	experimental	design	with	deliberate	disease	
induction;	however,	these	studies	will	not	be	included	in	further	steps	of	the	review.			
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Information	sources:			
	
We	will	conduct	the	literature	search	in	a	range	of	relevant	bibliographic	databases	and	other	
information	sources	containing	both	published	and	unpublished	literature.	Table	1	presents	the	
resources	to	be	searched.		
	
Table	1:		Databases	and	information	sources	to	be	searched	
	
Database	/	information	source	 Interface	/	URL	
MEDLINE,	 MEDLINE	 In-Process	 and	
MEDLINE(R)	Daily	Epub	Ahead	of	Print	
Ovid	SP	
CAB	Abstracts		 CAB	Interface	
Science	Citation	Index		 Web	of	Science	
Conference	 Proceedings	 Citation	 Index	 –	
Science	
Web	of	Science	
Agricola	 Proquest	
	
We	will	also	hand-search	the	table	of	contents	of	the	following	relevant	conferences	from	1997	
to	2018:	
• Proceedings	of	the	American	Association	of	Bovine	Practitioners;	
• 	World	Association	for	Buiatrics;	
• 	National	Mastitis	Council	Proceedings	
The FDA website containing the Freedom of Information New Animal Drug Approvals (NADA) 
summaries also will be searched.   
	
Search	strategy:			
	
A	Science	Citation	Index	(Web	of	Science)	search	strategy	designed	to	identify	studies	of	
antibiotic	treatments	during	the	dry-off	period	in	dairy	cattle	is	presented	in	Table	2.	The	search	
strategy	employs	a	multi-stranded	approach	to	maximize	sensitivity.		The	conceptual	structure	
is	as	follows:	
	
•	 Dairy	cattle;		
AND	
•	 Internal	or	external	teat	sealants.		
	
Table	2:	Search	strategy	to	identify	studies	of	teat	sealants	during	the	dry-off	period	in	dairy	
cattle	in	Science	Citation	Index	(Web	of	Science)	
	
#	11	 #10	AND	#4	 552	
#	10	 #9	OR	#8	OR	#7	OR	#6	OR	#5	63,874	
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#	9	 TS=(bismuth*	OR	Teatseal*	OR	Orbeseal*	OR	"Orbe-seal*"	OR	LockOut*	OR	"Lock	Out*"	
OR	Boviseal*	OR	"Bovi-seal*"	OR	Cepralock*	OR	"Cepra-lock*"	OR	Noroseal*	OR	"Noro-seal*"	
OR	 THexx*	 OR	 "T-Hexx*"	 OR	 Ubroseal*	 OR	 "Ubro-seal*"	 OR	 DryFlex*	 OR	 "Dry-Flex*"	 OR	
StrongHold*	OR	"Strong	Hold*")	 47,458	
#	8	 TS=(("teat"	 OR	 "teats"	 OR	 intramammar*	 OR	 "intra-mammar*")	 NEAR/5	 barrier*)
	 29	
#	7	 TS=(("teat"	 OR	 "teats"	 OR	 intramammar*	 OR	 "intra-mammar*"	 OR	 "barrier")	 NEAR/5	
("dip"	OR	"dips"	OR	"dipped"	OR	"dipping"	OR	coat*	OR	film*))	 15,018	
#	6	 TS=((external*	OR	internal*	OR	persistent*)	NEAR/5	("seal"	OR	"seals"	OR	sealant*	OR	
"sealed"	OR	"sealing"	OR	sealer*	OR	plug*))	1,007	
#	5	 TS=(("teat"	 OR	 "teats"	 OR	 intramammar*	 OR	 "intra-mammar*"	 OR	 "barrier")	 NEAR/5	
("seal"	OR	"seals"	OR	sealant*	OR	"sealed"	OR	"sealing"	OR	sealer*	OR	plug*))	 590	
#	4	 #3	OR	#2	OR	#1	 495,342	
#	3	 TS=(mastiti*	OR	((intramammar*	OR	"intra-mammar*")	NEAR/3	(infect*	OR	inflamm*)))
	 16,589	
#	2	 TS=(ayrshire*	OR	"brown	swiss*"	OR	"busa"	OR	"busas"	OR	canadienne*	OR	dexter*	OR	
"dutch	belted*"	OR	"estonian	red*"	OR	fleckvieh*	OR	friesian*	OR	girolando*	OR	guernsey*	OR	
holstein*	 OR	 illawarra*	 OR	 "irish	 moiled*"	 OR	 jersey*	 OR	 "meuse	 rhine	 issel*"	 OR	
montbeliarde*	 OR	 normande*	 OR	 "norwegian	 red*"	 OR	 "red	 poll"	 OR	 "red	 polls"	 OR	
shorthorn*	OR	"short	horn*")	 53,936	
#	1	 TS=("cow"	OR	"cows"	OR	"cattle"	OR	heifer*	OR	"dairy"	OR	"milking"	OR	"bovine"	OR	
"bovinae"	OR	buiatric*)	 465,272	
	
The	search	strategies	will	not	be	limited	by	date,	language,	or	publication	type.			
	
We	will	 conduct	 searches	using	each	database	 listed	 in	 the	protocol,	 translating	 the	 strategy	
appropriately	to	reflect	the	differences	in	database	interfaces	and	functionality.			
	
Study	records:	
	
			 Data	management:		We	will	download	the	results	of	searches	in	a	tagged	format	and	load	
them	into	bibliographic	software	(EndNote).	The	results	will	be	de-duplicated	using	several	
algorithms.		We	will	save	results	from	resources	that	do	not	allow	export	in	a	format	
compatible	with	EndNote	in	Word	or	Excel	documents	as	appropriate	and	manually	de-
duplicate.		The	de-duplicated	search	results	will	be	uploaded	into	online	systematic	review	
software	(DistillerSR®,	Ottawa,	ON,	Canada).	Reviewers	will	have	training	in	epidemiology	and	
in	systematic	review	methods.		Prior	to	both	abstract	and	full-text	screenings,	data	extraction,	
and	risk	of	bias	assessment,	the	reviewers	assigned	to	each	step	will	undergo	training	to	ensure	
consistent	data	collection	using	the	forms	created	in	DistillerSR®.		
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				Selection	process:			In	the	first	round	of	screening,	abstracts	and	titles	will	be	screened	for	
eligibility.	Two	reviewers	will	independently	evaluate	each	citation	for	relevance	using	the	
following	questions:	
1)	Does	the	study	evaluate	the	use	of	internal	or	external	teat	sealants	in	pre-partum	dairy	
heifers	or	at	dry-off	in	dairy	cows	following	the	first	or	greater	lactation?		
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
2) Is	there	a	concurrent	comparison	group?	(i.e.	controlled	trial	with	natural	or	deliberate	
disease	exposure	or	analytical	observational	study)?	
YES	(neutral	response),	NO	(EXCLUDE),	UNCLEAR	(neutral	response)	
3) Is	the	full	text	available	in	English?	
YES	(include	for	full	text	screening),	NO	(EXCLUDE),	UNCLEAR	(include	for	full	text	
screening)	
	
Citations	will	be	excluded	if	both	reviewers	responded	“no”	to	any	of	the	questions.		Any	
disagreements	will	be	resolved	by	consensus.		If	consensus	cannot	be	reached,	the	article	will	
be	marked	as	“unclear”	and	will	advance	to	full	text	screening.		A	pre-test	will	be	conducted	by	
all	reviewers	on	the	first	250	abstracts	to	ensure	clarify	of	questions	and	consistency	of	
understanding	of	the	questions.	
Following	title/abstract	screening,	eligibility	will	be	assessed	through	full-text	screening.		The	
same	questions	will	be	used	as	for	the	title	/	abstract	screening.	Two	reviewers	will	
independently	evaluate	the	full	text	articles,	with	any	disagreements	resolved	by	consensus.	If	
consensus	cannot	be	reached,	a	third	reviewer	will	be	used.	
			Data	collection	process:		Data	will	be	extracted	by	two	reviewers	working	independently.		Any	
disagreements	will	be	resolved	by	consensus	or,	if	consensus	cannot	be	reached,	a	third	
reviewer	will	be	used.		Authors	will	not	be	contacted	to	request	missing	data	or	to	clarify	
published	results.		A	form	for	data	extraction	will	be	created	for	this	review	in	DistillerSR®	and	
pre-tested	on	4	full	text	articles	to	ensure	question	clarity.	
	
Data	items:		
	
Study	level	data	to	be	extracted	include:	
• Study	design:	experimental	with	natural	disease	exposure,	experimental	with	deliberate	
disease	exposure	(“challenge	trial”),	or	analytical	observational	
• Country	
• Commercial	versus	research	trials	
• Year	the	study	was	collected	
• Months	of	data	collection	
• Breed	of	cattle	
• Whether	 the	 study	 population	 is	 comprised	 of	 pre-partum	 heifers,	 first	 lactation	 or	
greater	dairy	cows	or	both	
 6 
• Description	of	 the	 intervention	 (specific	 teat	 sealant)	 and,	 for	 pre-partum	heifers,	 the	
time	pre-partum	when	the	intervention	was	applied	
• Description	of	comparison	group	
	
The	 above	 data	 will	 be	 collect	 for	 all	 of	 the	 primary	 hypothesis-testing	 studies	 that	 are	
identified	 as	 relevant	 at	 full	 text	 screening	 (i.e.,	 experimental	 studies	 with	 natural	 disease	
exposure,	experimental	studies	with	deliberate	disease	induction,	and	analytical	observational	
studies).	 	The	arm	level	data,	described	below,	will	be	extracted	only	for	experimental	studies	
with	natural	disease	exposure.	
	
Arm	level	data	collected:	
• Number	of	animals	enrolled	
• Number	of	animals	lost	to	follow	up	
• Number	of	animals	analyzed	
• Any	 additional	 concurrent	 treatments	 given	 to	 the	 intervention	 groups	 –	 studies	with	
additional	 treatments	will	 be	 considered	 as	 separate	 treatments	 arms	 to	 studies	with	
only	an	internal	or	external	sealant.		
	
Outcomes	and	prioritization:			
	
Critical	outcomes	(in	order	of	prioritization):	
- Incidence	of	clinical	mastitis	during	the	first	30	days	of	the	subsequent	lactation,	
- Reduction	in	new	IMI	during	the	dry-cow	period	or,	in	pre-partum	heifer,	the	period	
between	treatment	and	calving,	
- Reduction	of	new	IMI	during	the	first	30	days	of	lactation.			
Secondary	outcomes	(in	order	of	prioritization):	
- Total	antibiotic	use	to	treat	clinical	mastitis	during	the	first	30	days	of	the	subsequent	
lactation,	
- Milk	production	during	the	subsequent	lactation,	
- Somatic	cell	count	the	first	test	of	the	subsequent	lactation,	or	the	average	of	the	first	3	
tests	of	the	subsequent	lactation,	
- Risk	of	culling	due	to	mastitis	during	the	subsequent	lactation.	
These	outcomes	were	prioritized	based	on	their	impact	on	animal	health	and	welfare	and	their	
economic	importance.		Formal	evaluation	of	these	criteria	for	prioritization	was	not	
undertaken.	
	
Data	will	be	collected	to	describe	the	outcomes	that	were	evaluated	for	all	eligible	studies,	
regardless	of	study	design.		The	specific	outcome	data,	as	described	below,	will	be	extracted	
only	for	experimental	studies	with	natural	disease	exposure.	
	
Outcome	data	to	be	collected:	
1) Incidence	of	clinical	mastitis	during	the	subsequent	lactation	
a. Case	definition	of	clinical	mastitis	
b. Level	at	which	outcome	data	were	measured	(quarter,	composite	individual)	
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2) Outcomes	related	to	IMI	
a. Method	of	determining	the	study	subjects	were	free	of	IMI	at	dry-off	or,	for	pre-
partum	heifer,	prior	to	administering	the	intervention:	
i. Negative	culture	(extract	data	on	quarter	or	composite)	
ii. Somatic	cell	count	below	a	threshold	(extract	data	on	threshold	and	time	
period	for	assessment)	
iii. No	clinical	case	of	mastitis	during	specified	duration	(extract	data	on	
duration)	
iv. Other	(specify)	
v. Not	assessed	–	excluded	from	meta-analysis,	as	cannot	distinguish	
incident	from	prevalent	cases.			
b. Level	at	which	the	outcomes	were	measured	(quarter,	composite	individual,	
group)	
c. Method	of	diagnosis	of	IMI	status	
i. Number	of	milk	samples	used	to	classify	IMI	status	and	timing	of	sample	
collection	if	>	1		
ii. Whether	National	Mastitis	Council	(NMC)	Laboratory	Methods	were	
stated	as	used			
iii. If	other	methods	were	used	in	parallel	or	exclusively	e.g.	PCR;	Petrifilm	or	
selective	media	
d. Type	of	bacteria:	
i. Individual	bacteria	results	will	be	extracted	for:	Coliforms,	Strep.	uberis,	
Strep.	agalactica,	Staph.	aureus	
ii. Grouped	bacteria	results	will	be	extracted	for:	Major	contagious	mastitis	
pathogens	(Staph.	aureus	and	Strep.	agalactia),	and	Major	environmental	
mastitis	pathogens	(Strep.	uberis	and	coliforms)	
	
For	each	of	the	primary	and	secondary	outcomes,	we	will	extract	the	possible	metrics	in	the	
following	order:		
• 1st	priority:	Adjusted	summary	effect	size	(adjusted	risk	ratio	or	adjusted	odds	ratio,	mean	
differences	for	continuous	outcomes)	and	variables	included	in	adjustment	and	
corresponding	precision	estimate		
• 2nd	priority:	Unadjusted	summary	effect	size				
• 3rd	priority:	Arm	level	risk	of	the	outcome,	or	arm	level	mean	of	the	outcome	
(continuous	outcomes)	
• Variance	components.	
	
If	variance	estimates	are	not	reported,	but	the	authors	provide	the	data	necessary	to	calculate	
them	using	standard	formulas,	we	will	calculate	these	data.		If	results	are	provided	only	in	
graphical	form,	we	will	estimate	the	numerical	results	using	WebPlotDigitizer	
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(https://automeris.io/WebPlotDigitizer/),	if	the	full	text	is	in	a	suitable	format	for	using	this	
resource.	
	
Risk	of	bias	in	individual	studies:		Risk	of	bias	will	only	be	assessed	for	controlled	trials	with	
natural	disease	exposure.		Risk	of	bias	assessment	will	be	performed	at	the	outcome	level	for	
each	of	the	critical	outcomes	using	the	Cochrane	risk	of	bias	instrument	(Higgins	et	all,	2016),	
with	the	signaling	questions	modified	as	necessary	for	the	specific	review	question.	The	ROB-
2.0	for	RCTs	will	be	used.		This	tool	is	available	at	
https://sites.google.com/site/riskofbiastool/welcome/rob-2-0-tool.	
	
Data	synthesis:		
	
Network	meta-analysis.	Network	meta-analysis	(aka	mixed	treatment	comparison	meta-
analysis)	will	be	conducted	for	each	of	the	primary	outcomes.		Network	meta-analysis	will	use	
the	approach	described	by	NICE	Decision	Support	Unit	technical	document	(Dias	et	al.,	2014;	
O’Connor	et	al.,	2013,	O’Connor	et	al.,	2016).	The	approach	to	reporting	will	use	the	PRISMA-	
NMA	(http://www.prisma-statement.org/Extensions/NetworkMetaAnalysis.aspx).		Planned	a	
priori	sub-group	analyses	will	be	conducted	for	randomized	versus	non-randomized	trials,	
heifers	versus	first	lactation	or	older	cows,	and	internal	versus	external	sealants.		
	
Meta-bias(es):		Small	study	effects	(“publication	bias”)	will	be	assessed	for	all	antibiotic-
comparator	combinations	where	there	are	at	least	10	studies	in	the	meta-analysis.	If	feasible,	
we	will	use	approaches	to	assessing	publication	bias	in	the	network	of	evidence	using	
previously	proposed	approaches	(Mavridis	et	al.,	2013;	Mavridis	et	al.,	2014).		
	
Confidence	 in	cumulative	evidence:	 	The	quality	of	evidence	for	each	critical	outcome	will	be	
assessed	using	the	approach	proposed	by	GRADE	(GRADE,	2015,	Puhan	et	al.,	2014),	while	also	
considering	the	nature	of	the	network	meta-analysis	(Jansen	et	al.,	2011)	
Discussion:		
	
This	systematic	review	will	provide	a	synthesis	of	the	current	evidence	regarding	the	efficacy	of	
teat	sealants	used	pre-partum	in	heifers	and	at	dry	off	in	dairy	cows	to	prevent	IMI	and	clinical	
mastitis.		Results	will	be	helpful	for	veterinarians	and	dairy	producers	when	making	evidence-
informed	decisions	regarding	dry	cow	management	to	reduce	mastitis	and	potentially	reduce	
the	need	to	use	antibiotics	in	dairy	cows	at	dry	off	or	to	treat	clinical	disease.		The	results	also	
will	be	helpful	for	identifying	specific	gaps	in	knowledge	related	to	the	efficacy	of	these	
products	for	targeting	additional	research.	
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